不在港股通股价也狂飙,PD-(L)1/VEGF双抗热潮下,宜明昂科有“几把刷子”?

Ofweek维科网
12 Jun

当前赚足眼球的创新药品种有哪些?那必然有PD-(L)1/VEGF双抗。近段时间,这类产品可以说拉满了关注度。相关事件可不少。比如,三生制药及附属公司三生国健与辉瑞公司就PD-1/VEGF双特异性抗体SSGJ-707达成合作协议,交易总额(包括首付款、里程碑付款)高达60.5亿美元;在2025年ASCO年会上,康方生物与Summit合作的PD-1/VEGF依沃西单抗全球III期HARMONi研究公布...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10